Mochida Pharmaceutical (4534) FY2027 Q1 Earnings Report

Quick View

Executive Summary

The current Q1 results can be characterized as clearly demonstrating a trend of higher revenue and earnings, driven by double-digit revenue growth alongside progress in SG&A efficiency. Revenue was ¥317.2B (+19.1% year on year), while operating income was ¥35.6B (+38.5%), with earnings growth exceeding revenue growth. Ordinary income was ¥41.9B (+50.5%), and net income attributable to owners of the parent was ¥31.8B (+67.8%), with the growth rate expanding at each successive earnings level. The primary drivers of earnings growth were operating leverage resulting from the decline in the SG&A ratio (35.1%, compared with 41.5% in the previous year), as well as contributions from nonrecurring factors such as equity-method investment income and gains on sales of investment securities of ¥6.9B.

Factors Affecting Business Performance

【Revenue】Although the only reported segment is the Pharmaceutical-Related Business and detailed disclosure by region and product is not provided, revenue increased by +19.1% to ¥317.2B from ¥266.3B in the previous year. The growth rate was below those of operating income (+38.5%) and ordinary income (+50.5%), highlighting that earnings expanded more rapidly than revenue.

【Profit and Loss】The gross profit margin declined by 4.9pt to 46.3% from 51.2% in the previous year, suggesting an increase in costs or a change in the product mix. Meanwhile, SG&A expenses increased only +0.6%, and the SG&A-to-revenue ratio improved by 6.4pt to 35.1% from 41.5% in the previous year. Consequently, the operating margin rose by 1.6pt to 11.2% from 9.7%. At the ordinary income level, non-operating income, including equity-method investment income of ¥3.8B and dividends received of ¥2.8B, contributed to growth, lifting the ordinary income margin to 13.2% from 10.5% in the previous year. Although a gain on sales of investment securities of ¥6.9B was recorded as extraordinary income, the effective tax rate increased to 34.7% from 31.9% in the previous year; nevertheless, net income increased substantially to ¥31.8B (+67.8%). In conclusion, the current results represent higher revenue and higher earnings.

Key Financial Indicators

【Profitability】The operating margin of 11.2% (9.7% in the previous year), ordinary income margin of 13.2% (10.5% in the previous year), and net income margin of 10.0% (7.1% in the previous year) all improved, while the gross profit margin declined by 4.9pt to 46.3% from 51.2% in the previous year. Accordingly, the improvement in profitability this period was primarily attributable to SG&A efficiency. 【Cash Quality】Quarterly turnover days relative to revenue and costs were approximately 107 days for trade receivables (125 days in the previous year), approximately 103 days for inventories (141 days in the previous year), and approximately 55 days for trade payables (68 days in the previous year). The resulting cash conversion cycle shortened by approximately 42 days to approximately 155 days from 197 days in the previous year, indicating an improving trend in working capital efficiency. 【Investment Efficiency】ROE based on net income attributable to owners of the parent was 2.3% (quarterly actual, before annualization), comprising a net income margin of 10.0%, total asset turnover of 0.17x (quarterly), and financial leverage of 1.29x. 【Financial Soundness】The equity ratio remained high at 77.3% (76.8% in the previous year), while ample liquidity was secured, with a current ratio of 394% and a quick ratio of 323%. Against long-term borrowings of ¥100B, the company held cash and deposits of ¥254.2B and investment securities of ¥372.9B. Interest expense was only ¥0.4B, indicating an extremely light interest-payment burden.

Cash Flow Analysis

As an individual cash flow statement is not disclosed, cash movements are analyzed based on changes in the balance sheet. Cash and deposits amounted to ¥254.2B, down ¥26.5B (-9.4%) from ¥280.6B at the end of the previous fiscal year. Retained earnings increased by only ¥17.6B; based on the difference from net income of ¥31.8B, approximately ¥14.2B is estimated to have been paid as dividends. Treasury stock increased to ¥35.9B from ¥32.7B at the end of the previous fiscal year, suggesting that approximately ¥3.2B was used for share repurchases. On the asset side, long-term prepaid expenses increased substantially from ¥50.7B to ¥183.4B, while other current assets declined significantly from ¥153.6B to ¥44.8B, possibly indicating a shift in funds from short-term assets to long-term assets. Total assets were ¥1814.2B, approximately unchanged from the previous fiscal year. Overall, the company appears to have allocated funds in a balanced manner between investment and shareholder returns while maintaining liquidity on hand.

Quality of Earnings

In terms of earnings quality, recurring earnings improvement was primarily driven by SG&A efficiency, suggesting relatively high sustainability. However, ordinary income was boosted by ¥7.1B in non-operating income, comprising equity-method investment income of ¥3.8B and dividends received of ¥2.8B, indicating a relatively large contribution from factors outside the core business. A gain on sales of investment securities of ¥6.9B was recorded as extraordinary income, representing a one-time factor. The effective tax rate increased to 34.7% from 31.9% in the previous year, and the higher tax burden acted to restrain the growth rate of net income (+67.8%) relative to the growth rate of profit before tax (+74.9%). Comprehensive income was only ¥17.0B, resulting in a ¥14.8B gap from net income of ¥31.8B. This was primarily due to a negative ¥14.5B change in the valuation difference on other securities, and comprehensive income also declined by -9.2% from ¥18.8B in the same period of the previous year. Despite substantial growth in net income, comprehensive income was below the previous year. The fact that changes in the market value of held securities reduced the ultimate increase in equity is an important consideration when evaluating earnings quality.

Earnings Forecasts and Guidance

The Q1 progress rates against the full-year company plan were 25.2% for revenue, 33.9% for operating income, 33.5% for ordinary income, and 31.8% for net income, with profit items progressing above the simple 25% benchmark. The full-year plan calls for revenue of ¥1260.0B (+7.7% from the previous fiscal year), operating income of ¥105.0B (+3.5%), and ordinary income of ¥125.0B (+11.6%). The growth rates in the current Q1—revenue +19.1%, operating income +38.5%, and ordinary income +50.5%—are therefore running ahead of the assumptions underlying the full-year plan. No revisions to the earnings forecast or dividend forecast were disclosed this time. The above-plan progress rates include contributions from nonrecurring factors such as equity-method investment income and gains on sales of investment securities. Toward the full year, the reversal of these one-time factors and trends in the gross profit margin will be key considerations in assessing the sustainability of progress.

Shareholder Returns

Under the company’s plan, the annual dividend forecast is ¥85 per share, and no revision to the dividend forecast had been made as of the current quarter. The payout ratio against the company’s planned EPS of ¥282.86 is approximately 30.0% (¥85/¥282.86), which remains at a reasonable level. Changes in the balance sheet during the current Q1 indicate that treasury stock increased from ¥32.7B to ¥35.9B, suggesting that approximately ¥3.2B was used for share repurchases. From the perspective of total shareholder returns, given the ample funds on hand—cash and deposits of ¥254.2B and investment securities of ¥372.9B—and the conservative financial structure, with long-term borrowings limited to ¥100B, the company appears to retain sufficient resources for shareholder returns.

Risk Factors

1. Decline in Gross Profit Margin: The gross profit margin declined by 4.9pt to 46.3% from 51.2% in the previous year. This appears to have been affected by higher costs or changes in the product mix. Although the decline was offset this period by SG&A efficiency (SG&A ratio -6.4pt), continued deterioration in the same direction could reduce the scope for further improvement in the operating margin.

2. Nonrecurring Earnings and Higher Tax Burden: The increase in ordinary income and net income includes nonrecurring factors such as equity-method investment income of ¥3.8B and gains on sales of investment securities of ¥6.9B. The effective tax rate also increased to 34.7% from 31.9% in the previous year. If these factors dissipate, the earnings growth rate may contract.

3. Risk of Valuation Fluctuations in Securities: The change in the valuation difference on other securities was negative ¥14.5B, and comprehensive income was limited to ¥17.0B, down -9.2% year on year. The company holds investment securities of ¥372.9B, creating a structure in which market fluctuations affect net assets and comprehensive income.

Industry Benchmarks (Reference; Compiled by the Company)

Profitability and Returns

The operating margin is below the industry median, whereas the net income margin exceeds the median, indicating differing positioning across the stages of the earnings structure.

Growth and Capital Efficiency

The revenue growth rate is substantially above the industry median, placing the company at a level within the upper group.

Source: Compiled by the Company

Key Points in the Financial Results

1. The SG&A ratio declined by 6.4pt to 35.1% from 41.5% in the previous year, lifting the operating margin. The fact that SG&A efficiency more than offset the 4.9pt decline in the gross profit margin is noteworthy as a change in the cost structure.

2. Turnover days for trade receivables and inventories (on a quarterly basis) both shortened from the previous year, and the cash conversion cycle improved from approximately 197 days to approximately 155 days. The improvement in working capital efficiency is positive from a cash efficiency perspective.

3. Net income increased substantially by +67.8% year on year, but comprehensive income was limited to ¥17.0B, down -9.2% year on year. Due to fluctuations in the valuation difference on securities, the ultimate increase in equity did not expand to the same extent as net income. The divergence between earnings growth in the income statement and the increase in equity on a comprehensive basis is an important point when evaluating the quality of the results.

Theoretical Share Price (Reference Value)

This is a reference range mechanically calculated solely from publicly disclosed data using a residual income model (Ohlson-type model with an explicit 5-year fade). It is not a forecast of the market share price or a recommendation to take any specific investment action.

Sensitivity: ¥3,650–¥3,863 at cost of equity ±1%; ¥3,747–¥3,759 at ω±0.1.

Notes:

• Because forecast ROE is below the cost of equity, the theoretical value is below book value per share.
• Net assets at the end of the quarter are used (there is a timing difference from the full-year forecast).
• Because net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model / Interest Rate Reference Month: 2026-06 / This value does not forecast or guarantee the future share price)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, and after consulting a professional adviser as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2027 Q1 was a strong top-line and operating-profit quarter for Mochida Pharmaceutical, although part of the net-income acceleration was supported by a non-recurring securities gain. Revenue rose 19.1% YoY to ¥31.72bn. Operating income increased 38.5% to ¥3.56bn, outpacing sales growth. Ordinary income grew 50.5% to ¥4.19bn, aided by higher non-operating income. Net income rose 67.8% to ¥3.18bn. The operating margin expanded by 158bp YoY to 11.2% from 9.7%. Gross margin, however, declined by 486bp to 46.3%, indicating higher production or product-cost pressure. The SG&A-to-sales ratio fell sharply by 644bp to 35.1%, more than offsetting the gross-margin contraction and evidencing substantial operating leverage. Net margin improved by 291bp to 10.0% from 7.1%. Ordinary profit included ¥0.28bn of dividend income and ¥0.38bn of equity-method earnings, supporting recurring non-operating earnings. Pre-tax profit additionally benefited from a ¥0.69bn gain on sales of investment securities, equivalent to 2.2% of quarterly revenue. This one-off gain explains a meaningful portion of the gap between the 50.5% increase in ordinary income and the 67.8% rise in net income. Comprehensive income declined 9.2% YoY to ¥1.70bn despite the increase in net income, principally reflecting a ¥1.45bn negative valuation difference on securities in OCI. The balance sheet remains highly liquid, with a 394.1% current ratio, 322.9% quick ratio, and 77.3% equity ratio. Leverage is low in absolute terms, with ¥10.0bn of interest-bearing debt, debt/capital of 6.7%, and interest coverage of 82.9x. The principal near-term operating issue is working-capital intensity: receivable days of 107, inventory days flagged at 194 days and 103 days under alternative calculations, and a 246-day cash-conversion cycle all require close monitoring. Management maintained its full-year forecast, and Q1 operating-profit progress of 33.9% is ahead of the standard 25% seasonal benchmark. The FY2027 outlook therefore depends on sustaining SG&A efficiency while preventing receivable and inventory intensity from absorbing the cash benefits of stronger earnings.

Profitability Analysis

The supplied annualized DuPont ROE is 9.1%, decomposed into a 10.0% net profit margin, 0.699x asset turnover, and 1.29x financial leverage. Financial leverage is conservative and stable in character, so the quarter's return improvement is primarily a profitability rather than balance-sheet leverage outcome. The largest operating change was SG&A efficiency: SG&A rose only 0.6% YoY to ¥11.12bn while revenue rose 19.1%, reducing the SG&A ratio to 35.1% from 41.5%. This favorable operating leverage more than offset the gross-margin decline to 46.3% from 51.2%. As a result, operating income grew twice as fast as revenue and operating margin reached 11.2%, a good level under the stated 8-15% benchmark. Net margin reached 10.0%, meeting the excellent benchmark, but it was enhanced by the ¥0.69bn gain on sale of investment securities. The tax burden was 0.653, corresponding to a 34.7% effective tax rate, while the interest burden of 1.365x reflects non-operating income exceeding financing costs rather than debt-related earnings pressure. Interest expense was only ¥0.04bn against EBIT of ¥3.56bn. The annualized 9.1% ROE is below the 10-15% good benchmark, indicating that substantial equity capital and modest asset turnover limit shareholder returns despite improved margins. Asset turnover of 0.699x on an annualized basis remains consistent with a balance sheet carrying substantial cash, receivables, inventories, and investment securities. Profitability sustainability will depend on whether the lower SG&A ratio reflects durable commercial productivity rather than quarterly timing, because gross-margin pressure leaves less room for cost inflation or product-mix deterioration.

Growth Assessment

Q1 revenue growth of 19.1% was materially above the 7.7% full-year revenue-growth assumption embedded in guidance. Q1 operating-income growth of 38.5% also exceeded the 3.5% full-year operating-income growth assumption, reflecting a favorable early-year margin mix and SG&A absorption. Revenue progress was 25.2% of the ¥126.0bn full-year forecast, broadly in line with the standard 25% Q1 pace. Operating-income progress was 33.9% of the ¥10.5bn forecast, 8.9 percentage points ahead of the standard pace but not more than 10 percentage points above it. Ordinary-income progress was 33.5% of the ¥12.5bn forecast, also ahead of normal Q1 seasonality. Net-income progress was 31.8% of the ¥10.0bn forecast, supported by the securities sale gain. The full-year forecast implies that growth and margins moderate materially after Q1, so the lack of a forecast revision is appropriately conservative. Revenue quality is supported by core operating profit growth, but the exceptional ¥0.69bn securities gain should not be extrapolated into run-rate earnings. The company operates in a single pharmaceutical-related reporting segment, making consolidated growth dependent on the performance of that core business. In pharmaceutical operations, reimbursement-price revisions, generic competition, product lifecycle changes, and manufacturing-cost inflation can quickly affect revenue growth and gross margins. The immediate indicators to assess sustainability are gross-margin stabilization, receivable collection, inventory normalization, and whether SG&A remains controlled as sales activity progresses through the year.

Financial Health

Financial health is strong. Current assets of ¥106.30bn exceeded current liabilities of ¥26.97bn by ¥79.33bn, producing a 394.1% current ratio and ¥79.33bn of working capital. The 322.9% quick ratio confirms that liquidity does not depend on inventory liquidation. Cash and deposits totaled ¥25.42bn, while accounts receivable totaled ¥37.29bn and inventories totaled ¥19.22bn. Total liabilities were ¥41.13bn against total equity of ¥140.29bn, with an equity ratio of 77.3%. Interest-bearing debt was limited to ¥10.0bn of long-term loans, and debt/capital was only 6.7%. The reported debt-to-equity ratio was 0.29x, well below the 2.0x warning threshold; using interest-bearing debt alone, debt relative to equity is even lower. Interest coverage of 82.9x demonstrates ample capacity to service financing costs. There is no maturity-mismatch concern evident from the reported structure because current assets exceed current liabilities by almost four times. Long-term loans are matched against a large equity base and substantial liquid assets. Net defined-benefit liability of ¥3.35bn is manageable relative to equity. Investment securities of ¥37.30bn represent 20.6% of total assets and are a meaningful source of market-value sensitivity, as shown by the negative OCI movement in the quarter.

Notable B/S Changes

Long-term prepaid expenses: +¥13.27bn YoY (+262%) to ¥18.34bn - a substantial reclassification or increase in deferred/long-term prepaid balances; this is a major driver of the change in non-current asset composition and warrants monitoring for recoverability and future expense recognition. Current assets: -¥12.72bn YoY (-10.7%) to ¥106.30bn - despite continued very strong liquidity, the decline reflects a changed current-asset mix. Cash and deposits: -¥2.65bn YoY (-9.4%) to ¥25.42bn - liquidity remains robust, but cash declined while operating working-capital balances remain high. Investment securities: -¥1.93bn YoY (-4.9%) to ¥37.30bn - still 20.6% of total assets; negative securities valuation OCI of ¥1.45bn demonstrates market-price sensitivity. Accumulated other comprehensive income: -¥1.48bn YoY (-11.1%) to ¥11.77bn - principally consistent with lower securities valuation reserves and explains why comprehensive income lagged net income. Provision for bonuses: -¥1.35bn YoY (-55.9%) to ¥10.61bn - a material reduction in accrued personnel costs, which may reflect payment timing or revised bonus accruals and should be assessed against subsequent SG&A trends.

Cash Flow Quality

Working-capital quality is the principal cash-conversion concern. The quality alert for DSO of 107 days indicates a long collection cycle relative to the 60-day threshold; accounts receivable increased 2.2% YoY to ¥37.29bn while Q1 sales grew 19.1%. The high receivable days may partly reflect pharmaceutical distribution and payment practices, but the level ties a substantial amount of capital to customer balances and should decline as sales mature through the fiscal year. Inventory days were flagged at 194 days and at 103 days under alternative inventory-day methodologies, both above their respective 90-day and 60-day thresholds. The root cause is the sizeable inventory base of ¥19.22bn, comprising ¥13.91bn of raw materials, ¥2.99bn of work in process, and ¥19.22bn of finished goods as separately reported. Although reported inventories declined 4.5% YoY, the flagged day levels indicate that inventory remains high relative to the current sales run rate. The 246-day cash-conversion cycle, versus the 120-day alert threshold, combines slow collection and inventory intensity and raises the risk that accounting earnings do not translate promptly into deployable cash. For a pharmaceutical manufacturer, safety-stock requirements, production lead times, and inventory held ahead of demand can structurally lengthen the cycle; nevertheless, elevated finished-goods exposure can also signal demand-forecast or product-mix risk. The investment implication is that continued profit growth should be evaluated alongside receivable aging and inventory turns, rather than on income-statement momentum alone.

Dividend Sustainability

The full-year dividend forecast is ¥85 per share and the full-year EPS forecast is ¥282.86, implying a dividend-only payout ratio of approximately 30.1%. This is comfortably below the 60% sustainability benchmark. The payout is supported by a strong capital base, low interest-bearing debt, and high reported liquidity. Retained earnings of ¥123.01bn provide substantial balance-sheet capacity. The company has not revised its dividend forecast. Dividend sustainability appears sound under the current earnings plan, although the pace of working-capital conversion remains relevant to the timing of internally generated cash available for distributions and reinvestment. No total return ratio is calculated because no share-buyback amount is provided.

Risk Assessment

Business risks include Pharmaceutical pricing, reimbursement reform, generic competition, and product-lifecycle dynamics could slow revenue growth or further compress the 46.3% gross margin., High finished-goods, raw-material, and work-in-process balances increase exposure to demand-forecast errors, product obsolescence, and manufacturing-cost volatility., The single pharmaceutical-related reporting segment concentrates operating performance in one core business rather than diversifying earnings across separately reported segments., A sustained rise in SG&A needed to support commercial activity could reverse the Q1 operating leverage that drove the 158bp operating-margin expansion..

Financial risks include DSO of 107 days is above the 60-day alert threshold, increasing receivable collection and customer-credit exposure., Inventory days flagged at 194 days and 103 days under alternative calculations exceed relevant thresholds, tying up capital and increasing inventory-management risk., The 246-day cash-conversion cycle exceeds the 120-day threshold and could delay the conversion of reported earnings into cash resources., Investment securities of ¥37.30bn, or 20.6% of assets, expose equity and comprehensive income to market valuation movements; securities valuation OCI was negative ¥1.45bn in Q1..

Key concerns include High receivable days: the root cause is a ¥37.29bn receivable balance relative to quarterly sales. While distribution terms can be structurally longer in pharmaceuticals, the 107-day level reduces cash efficiency and warrants monitoring of collection trends., High inventory days: the root cause is a large pharmaceutical production and finished-goods base. The inventory balance decreased YoY, which is favorable, but both flagged day measures remain elevated and leave the company exposed to inventory-aging risk., Long cash-conversion cycle: the root cause is the combined effect of extended receivables and inventory holding periods. Its impact is to make working-capital discipline central to assessing earnings quality even though balance-sheet liquidity is currently ample., Net income included a ¥0.69bn gain on sales of investment securities, so the 67.8% YoY net-income growth rate overstates underlying recurring earnings growth., Comprehensive income fell to ¥1.70bn from ¥1.88bn despite stronger net income, highlighting sensitivity of reported equity to securities-market movements..

Investment Implications

Key takeaways include Revenue, operating income, ordinary income, and net income all increased strongly, with operating profit growth of 38.5% materially exceeding sales growth of 19.1%., Operating-margin expansion to 11.2% was driven by SG&A leverage, despite a 486bp gross-margin contraction., Q1 operating-income progress of 33.9% is ahead of the normal 25% Q1 pace versus full-year guidance, while management has retained its forecast., The balance sheet is conservatively financed, with a 77.3% equity ratio, 6.7% debt/capital, and 82.9x interest coverage., Working-capital intensity and the non-recurring securities gain are the main qualifications to the otherwise strong earnings result..

Metrics to watch include Gross margin and SG&A-to-sales ratio, to determine whether Q1 operating leverage can be sustained., Accounts-receivable days and receivable aging, given the 107-day DSO alert., Inventory days, finished-goods trends, and cash-conversion-cycle improvement from the 246-day level., Progress against full-year operating-income guidance after the Q1 33.9% progress rate., Investment-security valuation movements and further gains or losses on securities sales..

Regarding relative positioning, Mochida Pharmaceutical combines good operating profitability, a 10.0% net margin, and exceptionally conservative liquidity and solvency. Its annualized 9.1% ROE is solidly improved but remains below the 10-15% good benchmark because asset turnover is modest and the equity base is large. Relative to the stated pharmaceutical operating benchmarks, the 11.2% operating margin is good, while working-capital efficiency is the principal relative weakness.